FDA reversal sets up high-stakes hearing on Sarepta gene therapy
Bio Pharma Dive
MARCH 17, 2023
The regulator will convene a panel of advisers to consult on an approval decision for the biotech’s Duchenne treatment, a change from just a few weeks ago when Sarepta had said a meeting wouldn’t be held.
Let's personalize your content